An invert oil-based mud (OBM) may include an oleaginous continuous phase, an aqueous internal phase, and an emulsifier. The emulsifier may include one or more of the group consisting of epoxidized methyl oleate, epoxidized methyl linoleate, and epoxidized methyl α-linolenate. The invert OBM may contain the emulsifier in an amount of the range of 0.1 to 10 wt. % (weight percent), relative to the total weight of the OBM.

An invert oil-based mud (OBM) may include an oleaginous continuous phase, an aqueous internal phase, and an emulsifier. The emulsifier may include one or more of the group consisting of epoxidized methyl oleate, epoxidized methyl linoleate, and epoxidized methyl α-linolenate. The invert OBM may contain the emulsifier in an amount of the range of 0.1 to 10 wt. % (weight percent), relative to the total weight of the OBM.

A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.

A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.

The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer’s disease; and/or in the treatment of cancer.

The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer’s disease; and/or in the treatment of cancer.

Described herein are compounds of the formulae (I)-(III) and (Ia)-(IIIa) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods using compounds of the formulae (I)-(III) and (Ia)-(IIIa) to, among other things, treat cancer. ##STR00001##

Described herein are compounds of the formulae (I)-(III) and (Ia)-(IIIa) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods using compounds of the formulae (I)-(III) and (Ia)-(IIIa) to, among other things, treat cancer. ##STR00001##

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed herein allows nitenin and nitenin analogue compounds to act as analgesic through reduction of K.sup.30 currents rather than their potentiation. Related to their high efficacy in the treatment of pain, these compounds are highly selective for slow voltage-activated potassium (K.sup.30 ) currents expressed in the small diameter dorsal root neurons (sDRGns), mainly on those mediated by the voltage-dependent potassium channel (K.sub.V), K.sub.V1.3. Such findings, together with those showing that nitenin and nitenin analogue compounds act as activity dependent blockers also lead to very reduced side-effects. The results disclosed herein show that nitenin and nitenin analogue compounds described herein are a viable alternative to the already existing pharmaceutical compounds used in the treatment of pain.